Streamlining BCBS Texas Skyrizi Prior Authorization Workflows

Understanding BCBS Texas Prior Authorization for Skyrizi (risankizumab)

Skyrizi, an IL-23 inhibitor (risankizumab) manufactured by AbbVie, is commonly prescribed for indications such as plaque psoriasis, psoriatic arthritis, and Crohn's disease. As a specialty medication, its prior authorization process with BCBS Texas involves distinct pathways depending on whether it falls under medical or pharmacy benefits. Klivira's platform is designed to manage these dual submission requirements effectively.

Key Submission Channels for Skyrizi with BCBS Texas

• **Medical Benefit Submissions:** For Skyrizi administered under the medical benefit (e.g., in-office infusions), BCBS Texas typically routes precertification requests through the BCBSTX provider portal and Availity Essentials. X12 278 transactions are also accepted via clearinghouses for impacted procedures.
• **Pharmacy Benefit Submissions:** When Skyrizi is covered under the pharmacy benefit, prior authorization workflows are managed by Prime Therapeutics, the PBM for BCBS Texas. Prescriber-initiated submissions can leverage ePA platforms such as CoverMyMeds and Surescripts.
• **Utilization Management Policy Access:** BCBS Texas publishes medical policies and clinical utilization management guidelines on its provider site, accessible via Availity. These policies outline specific criteria for specialty drugs, including potential step therapy requirements or quantity limits, which are crucial for a successful Skyrizi PA submission.

Navigating BCBS Texas Utilization Management Policies for Specialty Drugs

BCBS Texas's utilization management policies, available through Availity, specify the clinical criteria for specialty medications like Skyrizi. While some policies are HCSC-developed, others may incorporate criteria from sources like MCG or NCCN. It is critical to consult the most current, specific policy for risankizumab to ensure all documentation requirements are met, as state-specific policies for Texas may supplement corporate HCSC guidelines.

Common Prior Authorization Denial Reasons for Specialty Drugs like Skyrizi

• **Medical Necessity / Insufficient Documentation:** Lack of comprehensive clinical notes or failure to demonstrate medical necessity per BCBS Texas criteria.
• **Step Therapy Requirements:** Failure to document adherence to required preceding therapies or formulary alternatives.
• **Site-of-Service Mismatch:** Inappropriate billing for the location where the medication is administered.
• **Non-Formulary / Benefit Exclusion:** The drug may not be on the plan's formulary, or the specific indication may be excluded from benefits.

Expediting Prior Authorization Decisions and Appeals with BCBS Texas

BCBS Texas prior authorization turnaround times are governed by Texas Department of Insurance regulations for commercial plans and Texas Health and Human Services Commission (HHSC) rules for Medicaid managed care (STAR/STAR Kids). Additionally, BCBS Texas Medicare Advantage and Medicaid managed-care plans are subject to CMS-0057-F, mandating 72-hour standard and 24-hour expedited PA decision timeframes. In the event of a denial, BCBS Texas outlines a clear appeal pathway in its provider manual, with options for external review through the Texas Department of Insurance for commercial lines and CMS's 5-level appeal structure for Medicare Advantage.

Klivira's Role in Optimizing BCBS Texas Skyrizi Prior Authorization

Klivira integrates directly with EMRs and payer portals, including Availity and Prime Therapeutics, to automate the submission and tracking of BCBS Texas Skyrizi prior authorizations. Our platform streamlines documentation gathering, ensures adherence to payer-specific criteria, and provides real-time status updates, significantly reducing manual effort and improving turnaround times. This operational efficiency is critical for managing high-volume specialty drug authorizations.